Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872753 | 0.87 | CTSD (0.38) | MAPTALDH1A1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL4874303 | 0.85 | SLC6A4 (0.38) | L3MBTL1LMNASOAT2SOAT1POLB | |
| SCHEMBL4875458 | 0.81 | CYP3A4 (0.43) | ALDH1A1L3MBTL1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4875572 | 0.81 | CYP3A4 (0.43) | ALDH1A1L3MBTL1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4875374 | 0.80 | MTNR1A (0.45) | ALDH1A1L3MBTL1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4872513 | 0.80 | KMT2A (0.45) | MAPTALDH1A1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL4871432 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1L3MBTL1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4866667 | 0.77 | LMNA (0.45) | ALDH1A1L3MBTL1KMT2AMEN1LMNA | |
| SCHEMBL4679510 | 0.77 | CHRM3 (0.40) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL4875116 | 0.77 | ADAMTS5 (0.43) | L3MBTL1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | MAPT 4142/4885ALDH1A1 2504/4885L3MBTL1 2437/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | MAPT 4292/4885ALDH1A1 1684/4885L3MBTL1 2339/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | MAPT 4292/4885ALDH1A1 1684/4885L3MBTL1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.